Study at Japan's Kameda Medical Center Demonstrates Excellent Outcomes for Ibex's AI-powered Solution in Diagnosing Prostate and Breast Cancer

Results Published in the Journal Pathology

Kameda Adopts Ibex's Galen Prostate and Galen Breast to Support Pathologists in Primary Diagnosis

BOSTON and CHIBA, Japan, May 20, 2024 — Ibex Medical Analytics (Ibex), a global leader in AI-powered cancer diagnostics, and Kameda Medical Center (Kameda), a leading Japanese institute at the pinnacle of healthcare innovation, today announced the publication of a clinical study evaluating Ibex's Galen™ platform, published in the peer-reviewed journal Pathology1, which demonstrated excellent outcomes in detecting cancer and other pathologies in prostate and breast biopsies. The artificial intelligence (AI)-powered platform has subsequently been deployed at Kameda and is now supporting their pathologists in routine practice, integrated with their Philips IntelliSite Pathology Solution.

Ibex Logo

Kameda Medical Center Logo